Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.43 |
| ▸ | CA1 | P00915 | 13/20 | 0.40 |
| ▸ | CA12 | O43570 | 11/20 | 0.40 |
| ▸ | CA9 | Q16790 | 10/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.40 |
| ▸ | CA7 | P43166 | 8/20 | 0.40 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501064 | 0.86 | ENPP2 (0.53) | — | |
| SCHEMBL190203 | 0.84 | CA2 (0.44) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1365908 | 0.82 | ALDH1A1 (0.46) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17394036 | 0.82 | LMNA (0.44) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL16734814 | 0.81 | ALDH1A1 (0.44) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL6609666 | 0.79 | ALDH1A1 (0.43) | CA2CA1CA12CA9CA14 | |
| SCHEMBL54815 | 0.78 | MAPK1 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL19433226 | 0.78 | CA2 (0.42) | CA2CA1CA14CA7CA6 | |
| SCHEMBL16734881 | 0.76 | GAA (0.52) | ABCC9ABCC8KCNJ11PDK1PDK2 | |
| SCHEMBL3681691 | 0.76 | CA2 (0.45) | CA2CA1ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003671-B | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-108026110-B | Fused tricyclic compounds as protein kinase inhibitors | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2022-02-08 | — | — | CN | disclosed |
| EP-3341376-B1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO (ES) | 2020-12-23 | — | — | EP | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2019-02-19 | — | — | US | disclosed |
| US-20180244687-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-2714677-B1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-3341376-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III (F.S.P. CNIO) (ES) | 2018-07-04 | — | — | EP | disclosed |
| EP-1565466-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6909002-B2 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
| US-6420386-B1 | SPINAL TRAUMATISM, EPILEPSY, CHRONIC NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, SCHIZOPHRENIA, LATERAL AMYOTROPHIC SCLEROSIS OR HUNTINGTON'S CHOREA. | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | CA2 544/4885CA1 2092/4885CA12 3189/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | CA2 524/4885CA1 2774/4885CA12 4007/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | CA2 2766/4885CA1 4815/4885CA12 4852/4885 |
| US-20180244687-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK8, CDK18, CDK2 | CA2 3589/4885CA1 4093/4885CA12 4253/4885 |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | CDK8, CDK18, CDK2 | CA2 3589/4885CA1 4093/4885CA12 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.